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ABSTRACT  
Objectives: P-glycoprotein (P-gp), the product of the ABCB1 gene, is involved in the transport of 
aldosterone and cortisol in adrenal cells in vitro but its physiological role in humans remains 
controversial. Our objective was to test the influence of P-gp polymorphisms on aldosterone. 
Methods: We evaluated plasma aldosterone concentration (PAC), urinary aldosterone (UA), and blood 
pressure (BP) in a cohort of Caucasian normotensive men (i) at baseline on diets unrestricted for 
sodium and potassium and (ii) after a 5-day treatment with 500 mg b.i.d. clarithromycin, a P-gp 
inhibitor. Included were 20 homozygous wild-type (P-gp0), 20 heterozygous (P-gp1), and 20 subjects 
with combined 2677G>T/A-3435C>T loss-of-function polymorphism of the ABCB1 gene (P-gp2).  
Results: At baseline, PAC, UA, urinary free cortisol to urine creatinine ratios, and BP did not differ in 
the three genotypes. After clarithromycin administration, the UA to creatinine ratio (UAC) increased by 
an average of 30% in the entire cohort (p<0.001, n=60). Increases were pronounced in P-gp1 (+40%; 
p=0.014) and P-gp2 subjects (+50%; p=0.020) but lesser and were not significant in P-gp0 subjects 
(+10%; p=0.259). PAC also increased from baseline after clarithromycin treatment in all subjects 
(+19%, p=0.050); however, the increase in PAC was not significant when the three genotypes were 
analyzed separately.  
Conclusion: In our experimental conditions, the interaction between P-gp inhibition and the ABCB1 
genotype, suggests (i) that aldosterone is indeed a physiological endogenous substrate of P-gp in 
humans and (ii) that P-gp interferes with the net equilibrium between aldosterone secretion and 
elimination processes in humans.  
Clinical Trial Registration – URL: http://www.clinicaltrials.gov. Unique identifier: 
NCT01627665 
 
Keywords: P-glycoprotein, renin-angiotensin system, aldosterone, renin, polymorphism, 
ABCB1 gene, clarithromycin 
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INTRODUCTION 
P-glycoprotein (P-gp), also known as multi-drug resistance protein 1 (MDR1), is a transmembrane 
efflux protein encoded by the ABCB1 [ATP-binding cassette, sub-family B (MDR/TAP), member 1] gene 
in humans 1. It was first identified from multi-drug resistant cancer cells 2 and has since been shown to 
be present in normal human tissues such as proximal tubule of the kidney, bronchial cells, small 
intestine sweat glands, and capillary endothelium of brain, skin, testes, and adrenals 3. Its main 
functions are thought to be limiting absorption of xenobiotics from the gut, thus favoring their biliary 
and renal elimination, and protection of sensitive tissues (brain, testes) and fetal tissue from these 
compounds 4.  P-gp binds and transports a large number of drugs, playing an important role in their 
absorption and disposition 5. Drugs that bind to P-gp include potent antagonists of its function 6, 7. 
Various polymorphisms of the ABCB1 gene that alter its expression and/or function have been 
described 5, 8, 9. Among them, two single nucleotide polymorphisms (SNP) in linkage disequilibrium, 
2677G>T/A (rs2032582, p.A893S/T) in exon 21 and 3435C>T (rs1045642, p.I1145I) in exon 26 are 
common, particularly in Caucasians, and are associated with variations in P-gp expression and activity 
in humans and in cell lines 1. The SNP 3435C>T is associated with lower P-gp expression in B cell 
chronic lymphocytic leukemia and human duodenum in subjects with the TT genotype compared to 
the CT or CC genotypes. This mutation is associated with decreased transport activity of P-gp in vitro 
and in vivo 10, 11. Both 2677G>T/A and 3435C>T SNPs were shown to alter pharmacokinetics of drug 
metabolism 9. 
P-gp also transports several steroid hormones including corticosterone, cortisol, aldosterone, and 
progesterone and plays a protective role against accumulation of these hormones in the brain, heart, 
and testes 12-14. The high expression of P-gp in adrenal glands and its ability to transport steroids in 
vitro led to the hypothesis that P-gp contributes to aldosterone and cortisol secretion from the adrenal 
cortex in vivo 15. The physiological relevance of these findings is unclear, and data supporting this 
hypothesis are scarce.  A decrease in plasma cortisol and an increase in plasma aldosterone 
concentrations were reported in the postmenstrual phase of women with the homozygous 3435C>T 
genotype 16. Moreover, cyclosporine A, a potent P-gp inhibitor, was shown to inhibit the angiotensin II-
mediated stimulation of aldosterone secretion by glomerular adrenal cells in vitro 17, suggesting that P-
gp may contribute to the relative adrenal resistance (high renin/low aldosterone concentrations) 
observed in patients treated with this drug 18. Finally, ABCB1 gene polymorphisms were shown to 
influence blood pressure (BP) and response to treatment, and this effect is modified by salt intake 19, 20. 
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We investigated the physiological role of P-gp in humans by (i) studying the impact of the combined 
2677G>T/A-3435C>T loss-of-function polymorphism of the ABCB1 gene on the concentration of 
aldosterone and (ii) analyzing the impact of ABCB1 status on plasma renin concentration, potassium 
and sodium metabolism, and BP in normotensive healthy men. In addition, we studied for the first 
time the effects of pharmacologic inhibition of P-gp and CYP3A4 by clarithromycin in these subjects.   
METHODS 
Study participants 
This substudy testing the influence of P-gp on aldosterone and renin concentrations was nested within 
the DRIVING study, which was designed to test the influence of the ABCB1 genotype and 
clarithromycin on the pharmacokinetics of a single dose of new oral anticoagulant drugs dabigatran 
etexilate and rivaroxaban 21. The study was approved by the Comité de Protection des Personnes Ile de 
France X and the Agence Nationale de Sécurité des Médicaments and registered on 
www.clinicaltrial.gov registry (NCT 01627665). All participants gave their written informed consent to 
participate.  
Healthy Caucasian male volunteers aged 18 to 45 years were recruited at two Clinical Investigation 
Centers in Paris, France (Georges Pompidou European Hospital and Paris-Est Pitié-Salpêtrière 
University Hospital). They were eligible if their supine office blood pressure (BP) was less than 140 and 
90 mmHg and their body mass index (BMI) was 18-28 kg/m², and their clinical, routine biochemical and 
ECG evaluations were normal. Exclusion criteria were a history of allergy, ongoing chronic disease, 
acute disease within the past 8 days, use of medication within the past 8 days, or history of substance 
abuse or tobacco or alcohol consumption. Sodium and potassium in the diet were unrestricted 
throughout the study.  
After genetic screening of 224 eligible subjects, we included 60 subjects according to their ABCB1 
genotype: 20 subjects were wild-type homozygous (P-gp0 group), 20 were heterozygous mutated (P-
gp1 group), and 20 were homozygous mutated (P-gp2 group) for the ABCB1 haplotype 2677G>T/A-
3435C>T, as previously reported 21. 
Study design 
The design of the DRIVING study was previously reported 21. For this substudy, all subjects were 
studied under basal conditions and after 5 days of oral administration of clarithromycin 500 mg b.i.d. 
Clarithromycin is a potent inhibitor of both P-gp and CYP3A4 21. On both study days, blood was 
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sampled at 09.00 a.m. after a 1-hour rest in the semi-recumbent position after an overnight fast.  
Subjects were instructed to collect a 24-hour urine sample the day before each visit. Supine office BP 
was measured with a validated electronic device (Welchalin VSM300, New York, USA). Subjects 
followed an unrestricted salt isocaloric diet. The dose and duration of clarythromycin administration 
selected for the study was previously shown to inhibit P-gp and CYP3A4 activities and to lead to a two-
fold increase in both rivaroxaban and dabigatran exposure 21. This was independent of the ABCB1 
genotype, which did not affect the pharmacokinetics of the two drugs. 
Laboratory methods 
Plasma and urine samples were stored at 20 °C until analysis. Plasma renin concentration (PRC) was 
measured using an immunoradiometric assay (Renin III, CisBio, Codolet, France). Plasma aldosterone 
concentration (PAC) and 24-h urinary excretion of free aldosterone at pH1 (UAE) were measured using 
a radioimmunoassay (Coat-a-count, Siemens Medical Solutions Diagnostics, Erlangen, Germany). 24-h 
urinary free cortisol Excretion (UFCE) was measured by radioimmunoassay (Cortisol RIA kit, Beckman 
Coulter).  The ratio of UAE and UFCE to urinary creatinine excretion was used to standardize the 24-
hour urine collection. Glomerular filtration rate (GFR) was estimated with the simplified modification 
of diet in renal disease (MDRD) formula. To account for differences in diet between genotypes and 
visits, if any, 24-hour urinary sodium and potassium excretion were measured. All biochemical and 
hormonal assessments were performed blind to the genotype. 
 
Statistical analysis 
We used analysis of variance for normally distributed variables or the Kruskal-Wallis non-parametric 
tests for non-normally distributed variables to compare the characteristics between genotypes. We 
used the Student’s paired t-test to compare hemodynamic and hormonal parameters before and after 
clarithromycin administration. We used linear regression with Pearson's coefficient of correlation to 
assess the relationships between variables.  Non-normally distributed variables were log-transformed 
where appropriate because of skewed distribution. 
Data are expressed as means ± one standard deviation (SD) or as medians [interquartile range, IQR]. 
We used SPSS 20.0.0 program (SPSS, Chicago, IL, USA) for statistical analysis. A P value of <0.05 was 
considered as statistically significant. 
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RESULTS 
The median age of the healthy male subjects was 28.1 [23.8-38.9] years and their BP was 114 ± 8/68 ± 
6 mmHg at baseline (Table 1). There was no significant difference in age, BMI, heart rate, systolic and 
diastolic BP, GFR, or plasma electrolytes between genotypes (Table 1). Dietary sodium and potassium 
intakes were similar as shown by the similar urinary sodium and potassium excretions between 
genotypes (Table 1). 
INFLUENCE OF 2677-3435 HAPLOTYPE ON RENIN, ALDOSTERONE AND CORTISOL CONCENTRATIONS 
At baseline, PAC, UAE, and PRC did not significantly differ between the three genotypes (Table 1). As 
expected, there was a significant positive correlation between log-transformed PAC and PRC (r=0.509, 
p<0.001) in the entire cohort (n=60), which was also observed within each of the three genotypes with 
no difference in the slope of the intercept of the relationship between genotypes. When P-gp1 and P-
gp2 subjects (n=40) were grouped and compared to P-gp0 (n=20) subgroups, there were not 
statistically significant differences in PAC (+0%, p=0.983), PRC (-18%, p=0.159), or UAE (+ 11%, p=0.606, 
P-gp1-2 vs. P-gp0, respectively). There was no difference of UFCE to urinary creatinine excretion 
between genotypes. 
 
EFFECT OF CLARITHROMYCIN ON ALDOSTERONE, RENIN AND CORTISOL 
After 5 days of oral clarithromycin administration, there were no significant changes from baseline in 
BP or HR when the entire cohort (n=60) was considered (114 ± 8/68 ± 6 mmHg vs. 114 ± 8/69 ± 6 
mmHg, p=0.490 for systolic BP and p=0.239 for diastolic BP; 62 ± 9 vs. 62 ± 10 beats per minute, 
p=0.947). The urinary sodium and potassium to creatinine ratios remained stable indicating that 
dietary intake did not change. In the whole cohort urinary sodium excretion was 136 ± 55 mmol per 
day (p=0.190 vs. baseline) and urinary sodium to creatinine ratio was 10.4 ± 4.4 (p=0.956 vs. baseline). 
Potassium urinary excretion was 6.3 ± 2.1 mmol per day (p=0.836 vs. baseline) and urinary potassium 
to creatinine ratio was 9.4 ± 1.7 (p=0.413 vs. baseline). After 5 days of clarithromycin, there were no 
significant difference between subgroups of P-gp for urinary sodium excretion (p=0.329), urinary 
sodium to creatinine ratio (p=0.570), potassium urinary excretion (p=0.768) and urinary potassium to 
creatinine ratio (p=0.608). In the entire cohort (n=60), PAC increased slightly from baseline (+19%, 
p=0.050); however, PAC change from baseline were not significant in any of the three genotypes. 
There were no significant changes from baseline in PRC in the overall population or in the three 
genotypes. After treatment, PRC was lower in the P-gp0 groups than in the two other subgroups (P-
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gp0: 15 [11-21] vs. P-gp1 and P-gp2: 20 [15-31] p=0.043). The relationship between log-transformed 
PAC and PRC after 5 days of of oral clarithromycin administration was similar to that at baseline.  
In contrast, the UAC increased after 5 days of clarithromycin in the whole population (+30%, p<0.001). 
Differences were significant in P-gp2 subjects (48% [-3%; +134%] p=0.020) and P-gp1 subjects (+39% 
[+0%; +99%]; p=0.014) but not in P-gp0 subjects (+11% [-16%; +50%]; p=0.259) (Table 2, Figure 1). 
Conversely, there was no difference of UFCE to urinary creatinine excretion after clarithromycin (Table 
2, Figure 1). 
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DISCUSSION 
In subjects without sodium or potassium restriction, we found no physiological influence of the 
combined 2677G>T/A-3435C>T loss-of-function polymorphisms of the ABCB1 gene on aldosterone 
concentrations (PAC, UAE, and UFC) or on downstream hormonal (PRC), hemodynamic (BP), or 
electrolyte consequences in healthy normotensive subjects. We then evaluated effects of 
clarithromycin, which inhibit P-gp as well as CYP3A4 activities, in wild-type homozygous (P-gp0), 
heterozygous mutated (P-gp1), and homozygous mutated (P-gp2) subjects. Treatment with 500 mg 
b.i.d. of clarithromycin for 5 days strongly increased urinary aldosterone excretion by approximately 
40% and less markedly increased PAC by approximately 20% in all subjects, without however 
influencing PRC, BP, or plasma electrolyte concentrations. Sodium and potassium intakes did not vary 
from baseline. The effects of clarithromycin were different between the genotypes. A significant post-
clarithromycin increase in urinary aldosterone excretion was observed in subjects bearing one or two 
copies of the 2677G>T/A and 3435C>T polymorphisms; however, there was no effect of copy number: 
P-gp1 subjects had a 39% [0%; 99%] increase and P-gp2 subjects a 48% [-3%; 134%] increase in urinary 
aldosterone excretion. In contrast, the post-clarithromycin increase in urinary aldosterone excretion 
was not significant (~ +10%) in P-gp0 subjects compared to baseline. The effect of clarithromycin on 
urinary aldosterone excretion in P-gp1 and P-gp2 subjects was not accompanied by any significant 
change in PRC. In our experimental conditions, the interaction between P-gp and CYP3A4 inhibition 
and the ABCB1 genotype suggests (i) that aldosterone, the main steroid hormone secreted by zona 
glomerulosa of the adrenal cortex, is indeed an endogenous and physiological substrate of P-gp in 
humans and (ii) that P-gp interferes in a complex way with the net equilibrium of aldosterone 
secretion and elimination processes in humans.  
Plasma aldosterone concentration reflects the balance between its pulsatile synthesis and release by 
the adrenal zona glomerulosa under the influence of various endogenous factors (angiotensin II, ACTH, 
potassium, dopamine, etc.) and its continuous clearance from the plasma by renal and biliary 
mechanisms with a half-life of around 30 minutes 22. In humans, P-gp may potentially be involved in 
aldosterone secretion by the adrenal cortex and in its clearance. Secretion of aldosterone from the 
zona glomerulosa was believed to occur by passive diffusion, a process favored by the relatively small 
size and high lipid solubility of the hormone, but it can be facilitated by active transmembrane 
transport 23. P-gp present at the level of adrenocortical cells may facilitate steroid efflux as shown in 
vitro 15, but its relative contribution to aldosterone transport may be minor in vivo. Indeed, conflicting 
and indirect data on the impact of loss-of-function P-gp polymorphisms on adrenal aldosterone 
secretion and circulating aldosterone concentrations have been reported. Various previous studies 
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have failed to identify any influence of the 2677G>T/A and 3435C>T polymorphisms on plasma 
aldosterone concentrations in basal conditions 14, 20, 24 However other studies found effects of P-g 
genotype on aldosterone during menstrual cycle (ref Nakamura) or in contrasted angiotensin II 
conditions. Zolk et al. indeed found that homozygosity for 3435C>T was associated with greater 
increases in PAC after angiotensin II infusion and a blunted response to an oral sodium load when 
compared to the wild-type and heterozygous subjects14. The authors postulated that the higher 
stimulation in PAC in the homozygous mutant group was related to a lower P-gp driven UAE in renal  
We did not detect any influence of the combined 2677G>T/A and 3435C>T loss-of-function 
polymorphisms on PAC in basal conditions in normotensive subjects. This effect was confirmed by the 
measurement of UAE, which integrates overall aldosterone secretion over 24 hours and is more 
sensitive than a single measurement of PAC, since aldosterone secretion is pulsatile and follows a 
circadian cycle 25 Concomitant changes in renal and biliary clearances of aldosterone may have masked 
a defect in aldosterone secretion by the adrenal cortex in subjects bearing the combined 2677G>C/T/A 
and 3435C>T SNPs. Indeed, P-gp is also expressed at the apical membrane of renal proximal tubule and 
liver cells 26.   
The increase in UAC and the concomitant (even milder) increase in PAC after clarithromycin intake 
suggests that a decrease in extrarenal biliary clearance of aldosterone may have occurred. CYP3A4 and 
P-gp are both highly expressed in the gastrointestinal tract and liver and act synergistically as a 
protective barrier to the bioavailability of orally dosed drugs. Thus, both CYP3A4 and P-gp inhibition 
may have inhibited biliary clearance of aldosterone. 
We however previously reported  similar impact of clarithromycin on both dabigatran and rivaroxaban 
exposures while only rivaroxaban is a substrate of CYP3A4) suggesting that clarithromycin effect on 
pharmacokinetics of these drugs mainly involves P-gP inhibition and do not dramatically affect 
CYP17A4 activity.” There was large inter-individual variability in clarithromycin-induced increase in 
UAC that was dependent in part on the ABCB1 genotype. Indeed, the effect of clarithromycin on UAC 
was considerable in both homozygous P-gp2 and heterozygous P-gp1 subjects, whereas it was small 
and not significant in wild-type homozygous P-gp0 subjects. The potential mechanisms underlying the 
genotypic-dependent heterogeneity of the aldosterone metabolism response to clarithromycin are 
summarized in Figure 2. 
Our results suggesting that aldosterone is a physiological substrate in humans may help to reconcile 
the conflicting results reported so far. P-gp exerts a protective role against accumulation of steroids 
hormones (corticosterone, cortisol, aldosterone, and progesterone) in the adrenals, the renal tubules 
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and the biliary tract and also in the brain, heart, and testes 12-14. Accordingly, after exogenous [3H]-
aldosterone administration, P-gp-deficient (mdr1a/1b-/-) mice have increased [3H]-aldosterone plasma 
concentrations accompanied by accumulation of radiolabeled hormone in the brain and heart as 
compared to wild-type mice, showing a key role of P-gp in modulating the effects aldosterone in these 
organs 12, 13. Whether higher exposure of the brain, cardiovascular system, and kidney to aldosterone 
exist in subjects with a loss-of-function polymorphism in the ABCB1 gene is unknown, but, if this is the 
case, it may explain some genotype-phenotype correlations reported in humans. Such phenotypes 
include a blunted natriuretic response to high sodium diet in healthy subjects bearing the 3435C>T 
SNPs 14, the linkage of 3435C>T SNPs with day-time systolic blood pressure 20 and the deleterious 
effect of 3435C>T SNPs on renal function in patients with chronic kidney disease 27.   
Our study has some limitations. First, the small sample size of our population may not have had 
enough power to detect the effect of P-gp polymorphism alone. Only normotensive men were 
included in our study and sodium dietary status was not controled. Moreover, we did not measure the 
effect of a salt load or angiotensin II infusion to stress the different genotypes 14. Finally, our study was 
not randomized trial with placebo administration and we cannot exclude a “time-effect” during 
clarithromycin administration. Finally, the short follow-up period may not be sufficient to ascertain 
differences with clinical relevance.  
In conclusion, we report no difference in basal PAC and UAE according to P-gp genotype in 
normotensive Caucasian healthy males on an ad libitum sodium and potassium diets. By stressing the 
genotype with clarithromycin, we selectively observed an increase in UAE secretion in subjects 
heterozygous or homozygous for the 2677G>T/A-3435C>T loss-of-function polymorphisms, showing 
that aldosterone is a physiological P-gp substrate and that P-gp is involved in aldosterone metabolism.  
Whether this genotype is associated with aldosterone accumulation into brain, cardiovascular, and 
renal tissues as observed in mdr1a/1b-/- mice will require further investigation.  
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LEGENDS FOR FIGURES 
FIGURE 1. Effect of clarithromycin and P-gp genotype on hormone levels: (A) plasma renin 
concentration (PRC), (B) plasma aldosterone concentration (PAC),   (C) Urinary aldosterone 
(UA)/creatinine ratio, and (D) urinary free cortisol excretion (UFC) / creatinine ratio by genotype 
before (white bars) and after 5 days of clarithromycin 500 mg b.i.d. (grey bars). Bars show the medians 
and interquartile ranges (Q1-Q3) for homozygous wild-type (P-gp0 group), heterozygous mutated (P-
gp1 group), and homozygous mutated (P-gp2 group) for haplotype 2677G>T/A-3435C>T subjects.  
 
FIGURE 2.    Potential influences of P-gp loss-of-function on aldosterone metabolism at baseline and 
after clarithromycin treatment: P-gp is expressed in many tissues and is potentially involved in adrenal 
secretion of aldosterone and in biliary and renal aldosterone clearance. P-gp protects tissues from 
aldosterone impregnation. No effect of the 2677G>T/A-3435C>T loss-of-function polymorphisms was 
observed at baseline (panel A). Under clarithromycin, a potent CYP3A4 and P-gp inhibitor, we observed 
an increase in UAE and an increase in plasma aldosterone concentration, compatible with a decrease 
in extrarenal/biliary clearance of aldosterone (panel B). This effect was significant in P-gp1 and P-gp2 
subgroups. 
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